Back

Initiation of sodium-glucose co-transporter-2 inhibitors in patients with heart failure in the acute medical setting

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 4 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Tjasa Furlan

Trbovlje General Hospital, Trbovlje (Slovenia)

7 More presentations in this session

Presentation thumbnail
Medication optimisation after acute heart failure hospitalisation: a current situation in a developing country
Doctor K. Lorlowhakarn (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Applicability of vericiguat in heart failure patients early post-discharge: a single-center study
Doctor M. Passos (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Impact of statins on mortality and re-hospitalization in acute heart failure patients
Doctor R. Rajan (Kuwait City, KW)
Abstract Slides Video
Presentation thumbnail
The eligibility of patients hospitalized for heart failure for rapid up-titration of guideline-directed medical therapy in the light of the STRONG-HF trial and the latest ESC heart failure guidelines
Doctor F. Banfi-Bacsardi (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on hypotension, titration and drug combination
Doctor M. Chou (Tainan, TW)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 4

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Initiation of SGLT2I during acute HF hospitalization or in the immediate period following discharge.
thumbnail
Congress Presentation
Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Changes in N-terminal pro b-type natriuretic peptide according to SGLT2 inhibitor utilization patterns in patients hospitalized for decompensated heart failure: a prospective cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources